Low-dose colchicine for kidney disease patients
Part of Bones, joints & muscles, Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if a low dose of colchicine, a medicine that reduces inflammation, can help improve blood vessel and bone health in people with moderate chronic kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You have moderate chronic kidney disease (stage 3).
- Your urine shows a high level of protein (albumin).
- You have evidence of calcium buildup in your heart arteries on a CT scan.
- You have at least one condition like high blood pressure, diabetes, high cholesterol, or a history of heart disease or stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination pill (polypill) and a medicine called colchicine to see if they can lower the risk of future heart attacks, strokes, or other artery problems. It is for people who already have a history of heart or blood vessel disease.
This trial tests whether a low-dose colchicine (LoDoCo) can help people with heart failure and inflammation feel better and exercise more. It is for adults 50 and older with HFpEF who have signs of inflammation in their blood.
This trial tests whether colchicine, a drug that reduces inflammation, can help prevent further heart problems or strokes in people with moderate chronic kidney disease. You may be eligible if you have kidney disease and have had a heart attack, stroke, or related event in the past.
This Phase 2 trial tests whether colchicine can reduce inflammation and improve heart function in people with kidney disease and a certain type of heart problem. If you qualify, you’ll be closely monitored for side effects and lab changes.
This trial tests whether a low dose of the anti-inflammatory drug colchicine can help people who have recently had a heart attack or unstable angina. It aims to see if colchicine reduces the risk of future heart problems.
This trial tests whether low-dose colchicine can reduce “residual” risk—future heart and blood-vessel problems—in people with peripheral artery disease (PAD). It targets PAD symptoms and complications like poor blood flow in the legs, even after certain procedures.
Hear when a new Chronic Kidney Disease Mineral and Bone Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.